Medicis and Ipsen Announce Submission of Reloxin in Aesthetics to the FDA

SCOTTSDALE, Ariz. and PARIS, Dec. 5, 2007 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) and Ipsen (Euronext: FR0010259150; IPN) today announced the submission of a Biologics License Application ("BLA") for the botulinum toxin type A, Reloxin(R)(1), in aesthetics to the U.S. Food and Drug Administration's ("FDA's") Division of Dermatology and Dental Products, within the Center for Drug Evaluation and Research. Medicis anticipates a response from FDA in approximately 10 months following FDA's receipt of the Reloxin(R) submission.